Blue Cross Blue Shield SD iTind Coverage Update

Coverage Determination and Eligibility

Coverage determination

Investigational determination: The use of a temporarily implanted nitinol device (e.g., iTind) for lower urinary tract symptoms due to benign prostatic hyperplasia is considered investigational

Evidence (meta-analysis, RCTs, single-arm studies) is insufficient to establish improvement in net health outcome.

Trial-based candidate criteria

Consider iTind when ALL of the following trial-based criteria are met:

Eligibility based on trials: Patient has symptomatic BPH with International Prostate Symptom Score (IPSS) ≥10IPSS >= 10

Supported by RCT eligibility and single-arm cohorts (Chughtai et al, MT-02, MT-06).

Objective obstruction: Peak urinary flow rate (Qmax) ≤12 mL/s measured with an adequate voided volume (as used in trials)Qmax <= 12 mL/s

Qmax entry criteria reported in RCT and cohort studies (typical baseline Qmax ~7.3 mL/s in cohorts).

Prostate size: Prostate volume within studied ranges (commonly 25–75 mL; some cohorts allowed volumes up to <120 mL)prostate volume 25-75 mL (typical)

Mean prostate volumes in cohorts ~37–40 mL; study protocols specified volume ranges.

Anatomic and clinical exclusions absent: No obstructive median lobe, no prior prostate surgery, no urethral stricture, no bladder stones, no active urinary tract infection, and no other listed exclusions (e.g., PVR >250 mL) per study criteriaabsence of listed exclusions

Exclusions enumerated in RCT and single-arm study protocols.

Pre-procedure testing and preparation: Normal urinalysis/urine culture and appropriate medication washout per study protocols; plan for device retrieval after approximately 5–7 daysnormal urinalysis/urine culture

Documented eligibility and device dwell time in MT-02/MT-06 cohorts.

Evidence and guideline context

Evidence summary for clinical effect (no explicit coverage criteria stated in this section of the policy):

Clinical evidence from cohorts: Single-arm MT-02 reported statistically significant improvements in total IPSS and IPSS-QoL through >4 years, and Qmax and PVR through 3 years; MT-06 reported improvements in IPSS urinary symptoms, IPSS-QoL, Qmax, and MSHQ-EjD at 6 months in men desiring ejaculatory preservation

Findings derive from prospective, multicenter single-arm studies (MT-02, MT-06).

Randomized evidence: One RCT (Chughtai et al) reported a higher proportion achieving ≥3-point IPSS improvement at 3 months (78.6% vs 60%; p=0.029) but no significant between-group differences in overall IPSS, IPSS-QoL, Qmax, SHIM, or IIEF; the trial had notable loss to follow-up and limited duration

RCT results provide mixed signals and have limitations that reduce confidence in net benefit.

Guideline and systematic review context: A Cochrane network meta-analysis found TIND may result in worse urologic symptom scores compared to TURP at short-term follow-up; NICE (2022) concluded evidence is limited and recommends use only with special arrangements for governance, consent, and audit or research; AUA guidelines (2021, amended 2023) do not directly address temporary nitinol implants

The use of a temporarily implanted nitinol device (e.g., iTind) for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia is considered investigational.

Key exclusions applied in the randomized trial and prospective cohorts included an obstructive median lobe, prior prostate surgery, prostate cancer, and neurologic or anatomic bladder or sphincter abnormalities (for example, neurogenic bladder or urethral stricture). Additional exclusions reported in study protocols were active urinary tract infection, PVR >250 mL, bladder stones, significant hemostatic disorders, impaired renal function, and immunocompromised states.

Guideline context is limited. The AUA 2021 guideline did not address temporarily implanted nitinol devices directly; a 2023 amendment references patient selection (prostate volume 25–75 g and absence of an obstructive median lobe) based on expert opinion. The NICE 2022 interventional guidance states the evidence is limited in quantity and quality and recommends use only with special arrangements for clinical governance, consent, and audit or research.

The rationale for the investigational determination is that available evidence — including a network meta-analysis, a single randomized trial, and two multicenter single-arm cohorts — is insufficient to establish a durable improvement in net health outcome. Limitations include low-certainty comparative data from the Cochrane network meta-analysis, an RCT with substantial loss to follow-up and short duration, and reliance on single-arm studies for longer-term outcomes; collectively these factors reduce confidence in comparative effectiveness and safety.

Systematic review and meta-analysis data raise concerns about comparative effectiveness: a 2021 Cochrane network meta-analysis found temporary implantable nitinol devices may result in worse urologic symptom scores compared with TURP at short-term follow-up (mean difference in IPSS ~7.5; low-certainty evidence). The single RCT reported a higher proportion achieving a ≥3-point IPSS improvement at 3 months for iTind versus sham (78.6% vs 60%, p=0.029) but no significant differences in overall IPSS, Qmax, or sexual function measures, and was limited by high attrition and short follow-up. Single-arm MT-02 and MT-06 cohorts reported symptom and flow improvements, but lack of randomized comparators limits inference on comparative effectiveness.

The policy does not include an explicit not medically necessary phrase for this technology; instead, it documents that evidence is insufficient to determine a net health benefit and therefore classifies the use as investigational. Guideline advice (NICE) and limitations of randomized evidence are cited to justify restricted use and recommend special governance if the procedure is performed.

Billing and Codes

Codes table referencedmixed

No codes listed

Covered CPT CodesCPTCovered

53865	Cystourethroscopy with insertion of temporary device for ischemic remodeling (i.e., pressure necrosis) of bladder neck and prostate
53866	Catheterization with removal of temporary device for ischemic remodeling (i.e., pressure necrosis) of bladder neck and prostate

HCPCSHCPCS

No codes listed

Qmax obstruction threshold

Qmax obstruction thresholdRates < 10 mL/sec are considered obstructed (peak urinary flow rate measured by uroflowmetry)

Study eligibility commonly usedTrial entry criteria frequently used Qmax ≤12 mL/s (measured with adequate voided volume) — note threshold for obstruction per policy is <10 mL/s

Measurement methodQmax is measured by uroflowmetry

Clinically meaningful IPSS change

Clinically meaningful IPSS changeMinimum change of 3 points or a minimum 30% change from baseline is considered clinically meaningful

Use in trials

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Provider Requirements and Action Items

Not applicable.

Prior authorization documentation recommended: Provide documentation supporting medical necessity, including baseline symptom scores and objective measures used in clinical studies (e.g., International Prostate Symptom Score [IPSS] ≥10). Document prior medical therapy trials and intolerance or inadequate response to medications when applicable.
Key documented eligibility criteria (study-like): IPSS ≥10; peak urinary flow rate (Qmax) ≤12 mL/s with a ~125 mL voided volume; prostate volume generally 25–75 mL (varied by study); normal urinalysis, CBC, and biochemistry. Ensure washout of BPH medications per study precedent when applicable (e.g., 1 month for α-blockers, 6 months for 5‑α‑reductase inhibitors).
Candidate exclusions commonly found in trials (document if present): obstructive median lobe; post-void residual (PVR) >250 mL; bladder stones; active urinary tract infection; history of prior prostate surgery; PSA >10 ng/mL or free PSA <25% (study-specific); hemostatic disorders; neurogenic bladder or sphincter abnormalities; bladder cancer; significant comorbid cardiac disease or uncontrolled diabetes.
Investigational treatment — potential denial: The use of temporarily implanted nitinol devices (e.g., iTind) is considered investigational for treatment of LUTS due to BPH; claims may be denied as investigational and not medically necessary.
Prior authorization and coding: If submitting for review, include clinical documentation described above. Report services using CPT 53865 for cystourethroscopy with insertion of temporary device and CPT 53866 for catheterization with removal of temporary device. Specify place of service (typically outpatient) and the surgical service type.

Clinical Background

Benign prostatic hyperplasia (BPH) commonly produces lower urinary tract symptoms (LUTS) including urinary frequency, urgency, nocturia, hesitancy, and weak stream. The iTind system is a temporarily implanted nitinol device intended to reshape the prostatic urethra via expanding nitinol struts, with device removal typically after 5–7 days.

Definitions and Device Description

IPSS / AUASI — definition and role

DefinitionInternational Prostate Symptom Score (IPSS) / American Urological Association Symptom Index (AUASI): validated questionnaires assessing urinary symptom severity (7 items) with total scores 0–35

Severity categoriesAUASI/IPSS severity: mild (≤7), moderate (8–19), severe (20–35)

Role in decision-makingUsed to categorize BPH symptom severity and to measure treatment response (change in total IPSS and IPSS-QoL are commonly reported outcomes)

iTind system — device components and implantation details

System componentsiTind system consists of a nitinol-based implant, delivery system, and retrieval kit

Implant characteristicsDevice composed of intertwined nitinol struts (tulip-shaped) that expand to apply circumferential force and reshape the prostatic urethra

OpenPayer

Temporarily Implanted Nitinol Device (iTind) for Benign Prostatic Hyperplasia

Coverage Determination and Eligibility

Billing and Codes

Provider Requirements, Prior Authorization, and Documentation

Clinical Background

Definitions and Device Description